PPP2R1A and neoplasm: Experimental validation using techniques such as immunohistochemistry (IHC), flow cytometry, or single-cell RNA sequencing (scRNA-seq) on LUAD patient tissues is needed to confirm these findings and precisely map PPP2R1A expression within specific cellular compartments of the tumor microenvironment.